3 Active Ingredients Maker, Contract Formulations Company and Branded Generics Leader Stocks With a Strong Future Roadmap: Divi's Laboratories, Innova Captab and Sun Pharma

Pharma ingredient, contract and generics stocks give investors a way to track businesses that sit close to everyday demand in India. Divi's Laboratories, Innova Captab and Sun Pharma cover an active ingredients maker, a contract formulations company and a branded generics leader.

This list covers three pharma ingredient, contract and generics stocks with complete current figures: Divi's Laboratories, Innova Captab and Sun Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Ingredient, Contract and Generics Stocks?

Pharma ingredient, contract and generics stocks are listed pharmaceutical companies that make active ingredients and custom synthesis products, manufacture formulations for other drug makers and sell branded medicines in India and global markets. Their earnings depend on launches, approvals and export demand.

Pharma Ingredient, Contract and Generics Stocks at a Glance

On valuation, Sun Pharma trades at a P/E below the industry P/E, while Divi's Laboratories and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing pharma ingredient, contract and generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma ingredient, contract and generics stocks can use the coming numbers to test whether growth is holding.

Why Do Pharma Ingredient, Contract and Generics Stocks Have a Strong Roadmap in India?

Pharma ingredient, contract and generics stocks have a strong roadmap in India because outsourcing of drug manufacturing, rising healthcare spending and new specialty launches keep widening the market for Indian pharmaceutical firms.

• Ingredient supply. Global drug makers source from Indian plants.
• Contract work. Pharma firms outsource formulation output.
• Branded medicines. Prescription brands support steady demand.

Why Divi's Laboratories Features Among These Pharma Ingredient, Contract and Generics Stocks

Among the pharma ingredient, contract and generics stocks on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Innova Captab Features Among These Pharma Ingredient, Contract and Generics Stocks

Among the active ingredient, formulation and global generics shares on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Why Sun Pharma Features Among These Pharma Ingredient, Contract and Generics Stocks

Among the three companies on this list, Sun Pharmaceutical Industries is India's largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.

The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.

Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore.

Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What to watch: Track specialty product launches, United States approvals and domestic prescription trends.

Divi's Laboratories vs Innova Captab vs Sun Pharma on Key Financials

The table below sets the three pharma ingredient, contract and generics stocks side by side on revenue, profit and margin, using reported figures.

Divi's Laboratories posts the highest return on equity in this group at 15.3%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with pharma ingredient, contract and generics stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Pharma Ingredient, Contract and Generics Stocks

Every theme carries risks that deserve a check before any decision. For these pharma ingredient, contract and generics stocks, the main points are: Long-term active ingredient, formulation and global generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma ingredient, contract and generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma Ingredient, Contract and Generics Stocks

Pharma ingredient, contract and generics stocks work best when investors track growth, valuation and return on equity side by side. Divi's Laboratories, Innova Captab and Sun Pharma each have a clear plan to expand. Based on the 27 October 2026 close, Divi's Laboratories trades at Rs 9,505.5, Innova Captab at Rs 1,062.6 and Sun Pharma at Rs 1,751.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma ingredient, contract and generics stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pharma ingredient, contract and generics stocks, set price alerts and get research-backed stock ideas.

What are pharma ingredient, contract and generics stocks?

Ans. Pharma ingredient, contract and generics stocks are listed pharmaceutical companies that make active ingredients and custom synthesis products, manufacture formulations for other drug makers and sell branded medicines in India and global markets. Their earnings depend on launches, approvals and export demand. This list looks at three of them, Divi's Laboratories, Innova Captab and Sun Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which pharma ingredient, contract and generics stocks are covered in this list?

Ans. This list covers Divi's Laboratories, Innova Captab and Sun Pharma. Based on the 27 October 2026 close, Divi's Laboratories traded at Rs 9,505.5, Innova Captab at Rs 1,062.6 and Sun Pharma at Rs 1,751.2. Their return on equity ranges from 12.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 19.5%.

Why do pharma ingredient, contract and generics stocks have a strong future roadmap in India?

Ans. Pharma ingredient, contract and generics stocks have a strong roadmap in India because outsourcing of drug manufacturing, rising healthcare spending and new specialty launches keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Ingredient supply. Global drug makers source from Indian plants. Contract work. Pharma firms outsource formulation output. Branded medicines. Prescription brands support steady demand. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

How has Sun Pharma performed financially?

Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What risks should investors check before buying pharma ingredient, contract and generics stocks?

Ans. Investors should check a few risks before buying pharma ingredient, contract and generics stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma ingredient, contract and generics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.